Journal article
Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)
- Abstract:
-
BACKGROUND:Evidence is conflicting about a causal role of inflammation in psychosis and, specifically, regarding antibodies binding to neuronal membrane targets, especially N-methyl-D-aspartate receptors. NMDAR, LGI1 and GABA-A antibodies were found more prevalent in people with psychosis than in healthy controls. We aim to test whether these antibodies are pathogenic and may cause isolated psychosis. The SINAPPS2 phase IIa double-blinded randomised controlled trial will test the efficacy and...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.1MB, Terms of use)
-
- Publisher copy:
- 10.1186/s13063-019-3336-1
Authors
Funding
Bibliographic Details
- Publisher:
- BioMed Central
- Journal:
- Trials More from this journal
- Volume:
- 20
- Issue:
- 1
- Article number:
- 331
- Publication date:
- 2019-06-07
- Acceptance date:
- 2019-03-28
- DOI:
- EISSN:
-
1745-6215
- Pmid:
-
31174586
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:1011709
- UUID:
-
uuid:353b3551-a52e-4951-8b73-0ed6ac8e3bac
- Local pid:
-
pubs:1011709
- Source identifiers:
-
1011709
- Deposit date:
-
2019-07-22
Terms of use
- Copyright holder:
- Lennox, B et al
- Copyright date:
- 2019
- Notes:
- © The Author(s) 2019. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record